Whilst GLP-1 receptor agonists are not prescribed solely for hypertension management, certain patient populations may derive particular benefit from their blood pressure-lowering effects alongside their primary metabolic indications
2,3 Demand has grown rapidly, raising questions about real-world uptake, prescribing patterns across clinical indications, and whether population-level BMI distributions are beginning to shift in response
Endocrinology 157 , 16601672 (2016)
00:05:36 No, but we presented our first findings about this at the diabetes meeting in Madrid in 1985
Thats not what supplements do, and anyone telling you otherwise is selling you something
When researchers looked at all participants regardless of whether they stuck with the medication, the numbers were similar: 11.5% versus 3%